Scleral Lens Evolution - Summary - MDSpire

Scleral Lens Evolution

This article will examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, and offer guidance to practitioners who seek to expand their therapeutic options.

  • By

  • Carl Kramer, OD

  • May 1, 2026

  • 23 min

Share

Objective:

To examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, highlighting their role in improving patient quality of life.

Key Findings:
  • Scleral lenses provide significant relief from symptoms of dry eye disease and ocular surface disorders.
  • They offer customized vision correction that can exceed that of spectacles and soft contact lenses.
  • Patients with conditions like Sjögren syndrome show marked improvement in symptoms and quality of life with scleral lens use.
Interpretation:

Scleral lenses are a valuable therapeutic option for patients with severe ocular surface disease, particularly when conventional treatments are ineffective.

Limitations:
  • The article does not provide specific data on long-term outcomes of scleral lens use, particularly regarding symptom recurrence and lens-related complications.
  • Further research is needed to establish standardized fitting and management protocols, especially for diverse patient populations.
Conclusion:

Scleral lenses represent an important advancement in the management of ocular surface diseases, offering significant relief and improved quality of life for patients with severe symptoms, particularly when conventional treatments are inadequate.

Original Source(s)

Scleral Lens Evolution

  • by Carl Kramer, OD

  • May 1, 2026

Related Content

New Medications for Dry Eye and Presbyopia

Topical miotics are approved for use in all adults with presbyopia, including post-LASIK patients and pseudophakes, and acoltremon is a treatment option for multiple dry eye subtypes, either as primary therapy or adjunctive treatment.

Study Provides Real-World Evidence for Inflammatory DED

Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.

When Vision Fluctuates, Look to the Tear Film First

Dr. Theriot discusses the differences between natural tear film and artificial tears—and why the change in moniker to "lubricating drops" is appropriate.